RBX2660 Reduces Recurrent C difficile Infections in Patients With Comorbid Conditions
Bacterial Infections General General Infectious Diseases Microbiome News Treatments

RBX2660 Reduces Recurrent C difficile Infections in Patients With Comorbid Conditions

Treatment with investigational, microbiota-based, live biotherapeutic RBX2660 reduced recurrent Clostridioides difficile infection (rCDI) in patients with rCDI and comorbid conditions, according to research presented at the American College of Gastroenterology (ACG) 2021 Annual Meeting, held…